Developer docs
API playgroundTry for free, no card

Search company profiles

Acandis

Full company profile

uuid0000v9c

Namestring
Acandis
Legal namestring
ACANDIS GmbH
Websiteurl
acandis.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Acandis GmbH is a privately held German medical device company founded in 2006 and headquartered in Pforzheim, Germany, specialising in neurovascular implants for the endovascular treatment of stroke and adjacent cerebrovascular diseases. Its portfolio spans devices for haemorrhagic stroke (ACCERO, ACCLINO and DERIVO families of braided and laser-cut stents and flow diverters), ischaemic stroke (APERIO hybrid stent-retriever thrombectomy devices, CREDO stents, NeuroSpeed PTA balloon catheters, CARESTO carotid stents) and access/delivery (NeuroBridge and NeuroSlider microcatheters). The proprietary HEAL Technology — an antithrombogenic fibrin/heparin surface coating that mimics the final step of natural haemostasis — is applied across multiple device lines and is the company's primary technical differentiator, supported by a granted patent and ongoing post-market clinical studies (REVISAR, REheal, ICARUS, CARESTAR, RECHRUT, HYBRID, RESOLVE).

The company operates a hybrid commercial model: it sells directly via 12 wholly-owned subsidiaries in Germany, the United States, France, the United Kingdom, Austria, Switzerland, Turkey, Brazil, India, Vietnam, Poland and Colombia, and reaches 60+ additional countries through authorised distributor agreements. Revenue is generated primarily through one-time hardware sales of single-use implantable devices to hospitals and interventional neuroradiology departments, with procedure-volume-linked procurement contracts. Customers are tertiary-care and university hospitals performing mechanical thrombectomy, stent-assisted coiling, flow diversion, and ICAD interventions; physician training and clinical support are embedded in the commercial motion via hands-on workshops at the Pforzheim academy and at hospital sites globally.

Acandis is founder-managed under CEO Dr. Andreas Schüßler, who has led the company since inception, and in May 2026 received a minority growth-equity investment from Lauxera Capital Partners' €520 million Lauxera Growth II fund. The company has expanded its addressable market beyond acute stroke into pulsatile tinnitus (SiREX Stent, in RESOLVE pivotal study) and visceral/peripheral aneurysms (DERIVO peripher), and was recognised three times (2022, 2024, 2025) as a TOP 100 Innovator among German mittelstand companies. Revenue is not publicly disclosed; the company employs 101–250 people across its German operations and international subsidiaries.

Short descriptiontext

Acandis GmbH is a privately held German medical device company that designs, manufactures, and sells neurovascular implants — stents, flow diverters, thrombectomy devices, and microcatheters — for the endovascular treatment of stroke and adjacent cerebrovascular diseases, serving hospitals and interventional neuroradiologists in 60+ countries via 12 direct subsidiaries and a distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPforzheim, Germany
HQ citystring
Pforzheim
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurovascular medical devices, stroke treatment devices, flow diverter stents, mechanical thrombectomy devices, intracranial aneurysm treatment
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Neurovascular Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Acandis develops, manufactures, and commercialises neurovascular medical devices for hospitals and interventional neuroradiology departments globally. Revenue is generated through direct sales via subsidiaries and through distributor networks, with medical devices sold as single-use implants typically quoted and procured on a contract or recurring hospital procurement basis.

acandis.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1HEAL Technology
Description

Proprietary antithrombogenic coating technology for stents and flow diverters that mimics natural hemostasis

acandis.com
Core offering1 text field

Acandis develops, manufactures, and commercialises miniaturised implantable medical devices for the endovascular treatment of neurovascular diseases, including braided and laser-cut stents, flow diverters, mechanical thrombectomy devices, PTA balloon catheters, and microcatheters for stroke treatment. The company sells single-use implants to hospitals and interventional neuroradiology departments through a global network of direct subsidiaries and distributors across 60+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • REVISAR study: Publication of clinical and angiographic outcomes for APERIO thrombectomy device in distal vessel occlusions (2025)
+2 more records
Product overview1 text field

Acandis is a German medical technology company specializing in neurovascular devices for stroke treatment. The product portfolio consists of three main categories: (1) Devices for Hemorrhagic Stroke including ACCERO® stents (braided, visible), ACCLINO® laser-cut stents, and DERIVO® flow diverters (braided self-expanding); (2) Devices for Ischemic Stroke including APERIO® hybrid thrombectomy devices, CREDO® stents for intracranial stenosis, NeuroSpeed® PTA balloon catheters, and CARESTO® carotid stents; (3) Access and Delivery products including NeuroBridge® catheters and NeuroSlider® microcatheters (including DLC variants). Many products are available with HEAL Technology coating for improved healing. The company also offers the SiREX® Stent for venous sinus stenosis treatment. Products are complemented by training programs, sizing support services, and clinical studies.

Product and service21 records
1DERIVO 2 Embolisation Device
CategoryFlow Diverter / Haemorrhagic Stroke
Description

Self-expanding braided flow diverter implant for the endovascular treatment of intracranial aneurysms through flow diversion, redirecting blood flow away from the aneurysm while maintaining patency of side branches. Designed for interventional neuroradiologists treating unruptured and ruptured aneurysms.

2DERIVO 2heal Embolisation Device
CategoryFlow Diverter / Haemorrhagic Stroke
Description

HEAL Technology-coated version of the DERIVO 2 flow diverter, with antithrombogenic fibrin/heparin surface that reduces thrombogenicity and supports faster endothelialisation in intracranial aneurysm treatment.

3DERIVO Embolisation Device
CategoryFlow Diverter / Haemorrhagic Stroke
Description

Original-generation braided, self-expanding flow diverter for intracranial aneurysm treatment, featuring high flexibility for atraumatic wall apposition.

4DERIVO mini Embolisation Device
CategoryFlow Diverter / Haemorrhagic Stroke
Description

Smaller-profile braided flow diverter designed for treatment of distal intracranial aneurysms, compatible with small delivery systems.

5DERIVO peripher Embolisation Device
CategoryPeripheral Embolisation Device
Description

Braided, self-expanding flow diverter for peripheral and visceral artery aneurysm treatment, featuring nitinol composite wires with platinum core and compatibility with 0.027–0.039 inch delivery systems. Not available in the United States.

6ACCERO Stent
CategoryBraided Stent / Haemorrhagic Stroke
Description

Braided microstent with platinum-nitinol composite wire technology for stent-assisted coiling of wide-necked intracranial aneurysms, providing full radiopacity and flexibility.

7ACCERO heal Stent
CategoryBraided Stent / Haemorrhagic Stroke
Description

HEAL Technology-coated version of the ACCERO braided microstent, with antithrombogenic surface for stent-assisted coiling of intracranial aneurysms.

8ACCERO Rex Stent
CategoryBraided Stent / Haemorrhagic Stroke
Description

Specialised variant of the ACCERO braided stent designed specifically for treatment of giant cerebral aneurysms via stent-assisted coiling.

9ACCLINO flex plus Stent
CategoryLaser-cut Stent / Haemorrhagic Stroke
Description

Low-profile laser-cut stent for treatment of wide-neck intracranial aneurysms with enhanced flexibility and improved deliverability.

10ACCLINO heal Stent
CategoryLaser-cut Stent / Haemorrhagic Stroke
Description

HEAL Technology-coated version of the ACCLINO laser-cut stent for wide-neck intracranial aneurysm treatment, with antithrombogenic surface.

11APERIO Hybrid Thrombectomy Device
CategoryMechanical Thrombectomy / Ischaemic Stroke
Description

Hybrid-cell design stent retriever for mechanical thrombectomy in acute ischemic stroke, combining open and closed cell design elements for effective clot engagement, visibility and trackability.

12APERIO Hybrid17|21 Thrombectomy Device
CategoryMechanical Thrombectomy / Ischaemic Stroke
Description

Next-generation hybrid thrombectomy stent retriever available in 1.7mm and 2.1mm sizes for treatment of distal and proximal vessel occlusions in acute ischemic stroke.

13CREDO Stent
CategoryIntracranial Stent / Ischaemic Stroke
Description

Self-expandable microstent for the treatment of intracranial atherosclerotic disease (ICAD) and acute indications, including rescue stenting.

14CREDO heal Stent
CategoryIntracranial Stent / Ischaemic Stroke
Description

HEAL Technology-coated version of the CREDO self-expandable microstent for intracranial stenosis and rescue stenting, with improved endothelialisation.

15NeuroSpeed PTA Balloon Catheter
CategoryPTA Balloon Catheter / Ischaemic Stroke
Description

Percutaneous transluminal angioplasty (PTA) balloon catheter for pre-dilation and treatment of intracranial arterial stenosis, used in combination with CREDO stents as part of Acandis' integrated ICAD Treatment System.

16CARESTO heal Stent
CategoryCarotid Stent / Ischaemic Stroke
Description

Third-generation carotid artery stent with HEAL antithrombogenic coating for the treatment of carotid artery disease, featuring high flexibility and full visibility.

17NeuroBridge Catheter
CategoryAccess / Delivery Catheter
Description

Intermediate catheter for neurovascular access and support during interventional procedures, used to facilitate delivery of therapeutic devices.

18NeuroSlider Microcatheter
CategoryAccess / Delivery Microcatheter
Description

Microcatheter for device delivery in neurovascular interventions, used as a delivery conduit for therapeutic devices such as stents and flow diverters.

19NeuroSlider DLC (Micro)Catheter
CategoryAccess / Delivery Microcatheter
Description

Dual-layer composite (DLC) microcatheter with enhanced trackability and support for delivery of flow diverters and other devices in neurovascular interventions. First Acandis product to receive CE certification under EU MDR (2023).

20SiREX Stent
CategoryVenous Sinus Stent
Description

Braided, fully radiopaque implant specifically designed for the treatment of disabling pulsatile tinnitus caused by lateral venous sinus stenosis. Currently under clinical investigation in the international RESOLVE study (78 patients across five European centres).

21ICAD Treatment System
CategoryIntegrated Treatment System / Ischaemic Stroke
Description

Integrated treatment system combining the CREDO heal self-expanding microstent with the NeuroSpeed PTA balloon catheter for comprehensive intracranial atherosclerotic disease (ICAD) treatment in a single-pass endovascular therapy approach.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Coordinating Principal Investigator site for the RESOLVE clinical study (SiREX Stent for pulsatile tinnitus). Prof. Emmanuel Houdart serves as Coordinating PI, with Dr. Alexis Guédon and Dr. Francesco Arpaia as clinical team members. The hospital is leading the international pivotal trial across five European centres with 78 patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key opinion leader site for multiple Acandis clinical studies. PD Dr. Maxim Bester is PI for the ACCERO (heal) PMCF registry (154 patients, NCT03957382) and the REheal study. UKE also hosts regular Acandis training workshops (DERIVO, ICA aneurysm training).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key clinical study site and training partner. PD Dr. Hannes Nordmeyer serves as coordinating PI for the CARESTAR study (536 patients, NCT07166731) and PI for the RECHRUT study (153 patients). The hospital hosts regular CREDO workshop training sessions.

4Universitätsspital Basel
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lead site for the ICARUS investigator-initiated study (498 patients) evaluating CREDO heal Stent and NeuroSpeed PTA Balloon Catheter for ICAD-related stroke, directed by Prof. Dr. Marios Psychogios. Acandis is listed as a collaborator.

acandis.com
5Universitätsklinikum Bonn
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Principal investigator site for the REVISAR PMCF study (130 patients, completed, results published 2025) evaluating APERIO thrombectomy devices. Prof. Dr. Franziska Dorn is the PI.

acandis.com
6Universitätsklinikum Magdeburg
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Principal investigator site for the REheal PMCF study (352 patients, NCT05543447) evaluating the DERIVO 2heal Embolisation Device. Prof. Dr. Daniel Behme is the PI.

acandis.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Acandis participates in the annual LINNC Paris conference (1–3 June 2026), a major neurointervention educational event, as an exhibitor and presenter of clinical data.

8ESMINT (European Society of Minimally Invasive Neurological Therapy)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Acandis has participated as an exhibitor at ESMINT annual congresses (2024 Marseille, 2025 Marseille, 2026 Marseille) and hosts an annual Distributor Meeting alongside ESMINT.

acandis.com
9SOBRICE (Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Acandis has participated at SOBRICE annual meetings (2021, 2022, 2024) in São Paulo, Brazil, supporting its Latin American distributor and subsidiary presence.

acandis.com
Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stryker's Neurovascular division (formed via the acquisition of Cerenovus-related assets and others) is a global leader in hemorrhagic and ischemic stroke devices, including flow diverters (Surpass), stent retrievers (Trevo), and detachable coils. Directly competes with Acandis' DERIVO flow diverters and APERIO thrombectomy devices across hospitals globally.

TypeEmerging player
Description

InspireMD develops neurovascular and carotid stents with mesh protection technology (CGuard). Comparable to Acandis' CARESTO carotid stent franchise and DERIVO flow diverter technology, serving overlapping customer base.

TypeBroad incumbent
Description

Cerenovus is J&J's neurovascular franchise offering a comprehensive portfolio of coils, flow diverters, stent retrievers, and access devices. Direct overlap with Acandis across both hemorrhagic (coils/flow diversion) and ischemic stroke (stent retrievers) categories.

4MIVI Neuroscience
TypeEmerging player
Description

MIVI Neuroscience develops stroke treatment devices including the Q Aspiration catheter and Revive SE stent retriever. Direct competitor to Acandis' APERIO thrombectomy line, with overlapping target customers in stroke centers.

TypeDirect peer
Description

Wallaby Medical (acquired by Phenox) develops the Avenir coil system and other neurovascular devices. Direct peer to Acandis in the aneurysm treatment category with overlapping geographic coverage and target customers.

TypeDirect peer
Description

Penumbra is a U.S.-listed neurovascular company specializing in mechanical thrombectomy (aspiration-based, e.g., RED, Jet), stroke catheters, and more recently embolization devices. Direct competitor to Acandis' APERIO stent-retriever thrombectomy franchise and increasingly in flow diversion, with a strong U.S. commercial footprint.

TypeDirect peer
Description

Rapid Medical is an Israel-based neurovascular company developing adjustable stent retrievers (Tigertriever) and flow diverters (Comaneci). Direct peer with comparable focus on ischemic and hemorrhagic stroke, recently acquired by MicroPort further escalating competitive intensity.

TypeBroad incumbent
Description

Medtronic's Neurovascular business (inheriting Covidien/Stryker-era assets) competes across the full stroke spectrum including Pipeline flow diverters and Solitaire stent retrievers. As one of the largest medical device companies globally, Medtronic's scale, hospital contracts, and R&D resources make it Acandis' most formidable direct competitor.

TypeDirect peer
Description

Phenox is a German neurovascular device company offering pCONUS stents, p64 flow diverters, and pRESET stent retrievers. A direct peer with similar product portfolio, German origin, and target customer base (interventional neuroradiologists) competing head-to-head with Acandis in Europe.

10MicroPort NeuroTech
TypeDirect peer
Description

MicroPort NeuroTech (part of Shanghai MicroPort Medical) develops and markets the Tubridge flow diverter and other neurovascular devices. Directly comparable to Acandis in flow diversion technology with competing global commercial reach, particularly in China and Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acandis

Neurovascular Medical Devicesacandis.com

Acandis GmbH is a privately held German medical device company that designs, manufactures, and sells neurovascular implants — stents, flow diverters, thrombectomy devices, and microcatheters — for the endovascular treatment of stroke and adjacent cerebrovascular diseases, serving hospitals and interventional neuroradiologists in 60+ countries via 12 direct subsidiaries and a distributor network.

What Acandis does

Acandis GmbH is a privately held German medical device company founded in 2006 and headquartered in Pforzheim, Germany, specialising in neurovascular implants for the endovascular treatment of stroke and adjacent cerebrovascular diseases. Its portfolio spans devices for haemorrhagic stroke (ACCERO, ACCLINO and DERIVO families of braided and laser-cut stents and flow diverters), ischaemic stroke (APERIO hybrid stent-retriever thrombectomy devices, CREDO stents, NeuroSpeed PTA balloon catheters, CARESTO carotid stents) and access/delivery (NeuroBridge and NeuroSlider microcatheters). The proprietary HEAL Technology — an antithrombogenic fibrin/heparin surface coating that mimics the final step of natural haemostasis — is applied across multiple device lines and is the company's primary technical differentiator, supported by a granted patent and ongoing post-market clinical studies (REVISAR, REheal, ICARUS, CARESTAR, RECHRUT, HYBRID, RESOLVE).

The company operates a hybrid commercial model: it sells directly via 12 wholly-owned subsidiaries in Germany, the United States, France, the United Kingdom, Austria, Switzerland, Turkey, Brazil, India, Vietnam, Poland and Colombia, and reaches 60+ additional countries through authorised distributor agreements. Revenue is generated primarily through one-time hardware sales of single-use implantable devices to hospitals and interventional neuroradiology departments, with procedure-volume-linked procurement contracts. Customers are tertiary-care and university hospitals performing mechanical thrombectomy, stent-assisted coiling, flow diversion, and ICAD interventions; physician training and clinical support are embedded in the commercial motion via hands-on workshops at the Pforzheim academy and at hospital sites globally.

Acandis is founder-managed under CEO Dr. Andreas Schüßler, who has led the company since inception, and in May 2026 received a minority growth-equity investment from Lauxera Capital Partners' €520 million Lauxera Growth II fund. The company has expanded its addressable market beyond acute stroke into pulsatile tinnitus (SiREX Stent, in RESOLVE pivotal study) and visceral/peripheral aneurysms (DERIVO peripher), and was recognised three times (2022, 2024, 2025) as a TOP 100 Innovator among German mittelstand companies. Revenue is not publicly disclosed; the company employs 101–250 people across its German operations and international subsidiaries.

Acandis firmographics

Firmographics
Name
Acandis
Legal name
ACANDIS GmbH
Website
https://acandis.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Acandis GmbH is a privately held German medical device company that designs, manufactures, and sells neurovascular implants — stents, flow diverters, thrombectomy devices, and microcatheters — for the endovascular treatment of stroke and adjacent cerebrovascular diseases, serving hospitals and interventional neuroradiologists in 60+ countries via 12 direct subsidiaries and a distributor network.
Ownership category
akta.pro rank

Acandis industry classification

Industry
Product category
Neurovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Neurovascular medical devices
  • Stroke treatment devices
  • Flow diverter stents
  • Mechanical thrombectomy devices
  • Intracranial aneurysm treatment

Where Acandis is headquartered

Location

Headquarters

HQ city
Pforzheim
HQ country
Germany
HQ region
Europe

Offices13 records

Markets served

Acandis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Acandis develops, manufactures, and commercialises neurovascular medical devices for hospitals and interventional neuroradiology departments globally. Revenue is generated through direct sales via subsidiaries and through distributor networks, with medical devices sold as single-use implants typically quoted and procured on a contract or recurring hospital procurement basis.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Acandis product offering

Product offering

Core offering

Acandis develops, manufactures, and commercialises miniaturised implantable medical devices for the endovascular treatment of neurovascular diseases, including braided and laser-cut stents, flow diverters, mechanical thrombectomy devices, PTA balloon catheters, and microcatheters for stroke treatment. The company sells single-use implants to hospitals and interventional neuroradiology departments through a global network of direct subsidiaries and distributors across 60+ countries.

Product overview

Acandis is a German medical technology company specializing in neurovascular devices for stroke treatment. The product portfolio consists of three main categories: (1) Devices for Hemorrhagic Stroke including ACCERO® stents (braided, visible), ACCLINO® laser-cut stents, and DERIVO® flow diverters (braided self-expanding); (2) Devices for Ischemic Stroke including APERIO® hybrid thrombectomy devices, CREDO® stents for intracranial stenosis, NeuroSpeed® PTA balloon catheters, and CARESTO® carotid stents; (3) Access and Delivery products including NeuroBridge® catheters and NeuroSlider® microcatheters (including DLC variants). Many products are available with HEAL Technology coating for improved healing. The company also offers the SiREX® Stent for venous sinus stenosis treatment. Products are complemented by training programs, sizing support services, and clinical studies.

Differentiator

Problem solved

Functional benefit

Brands

  • HEAL Technology: Proprietary antithrombogenic coating technology for stents and flow diverters that mimics natural hemostasis

Products and services

  • DERIVO 2 Embolisation Device Self-expanding braided flow diverter implant for the endovascular treatment of intracranial aneurysms through flow diversion, redirecting blood flow away from the aneurysm while maintaining patency of side branches. Designed for interventional neuroradiologists treating unruptured and ruptured aneurysms.
  • DERIVO 2heal Embolisation Device HEAL Technology-coated version of the DERIVO 2 flow diverter, with antithrombogenic fibrin/heparin surface that reduces thrombogenicity and supports faster endothelialisation in intracranial aneurysm treatment.
  • DERIVO Embolisation Device Original-generation braided, self-expanding flow diverter for intracranial aneurysm treatment, featuring high flexibility for atraumatic wall apposition.
  • DERIVO mini Embolisation Device Smaller-profile braided flow diverter designed for treatment of distal intracranial aneurysms, compatible with small delivery systems.
  • DERIVO peripher Embolisation Device Braided, self-expanding flow diverter for peripheral and visceral artery aneurysm treatment, featuring nitinol composite wires with platinum core and compatibility with 0.027–0.039 inch delivery systems. Not available in the United States.
  • ACCERO Stent Braided microstent with platinum-nitinol composite wire technology for stent-assisted coiling of wide-necked intracranial aneurysms, providing full radiopacity and flexibility.
  • ACCERO heal Stent HEAL Technology-coated version of the ACCERO braided microstent, with antithrombogenic surface for stent-assisted coiling of intracranial aneurysms.
  • ACCERO Rex Stent Specialised variant of the ACCERO braided stent designed specifically for treatment of giant cerebral aneurysms via stent-assisted coiling.
  • ACCLINO flex plus Stent Low-profile laser-cut stent for treatment of wide-neck intracranial aneurysms with enhanced flexibility and improved deliverability.
  • ACCLINO heal Stent HEAL Technology-coated version of the ACCLINO laser-cut stent for wide-neck intracranial aneurysm treatment, with antithrombogenic surface.
  • APERIO Hybrid Thrombectomy Device Hybrid-cell design stent retriever for mechanical thrombectomy in acute ischemic stroke, combining open and closed cell design elements for effective clot engagement, visibility and trackability.
  • APERIO Hybrid17|21 Thrombectomy Device Next-generation hybrid thrombectomy stent retriever available in 1.7mm and 2.1mm sizes for treatment of distal and proximal vessel occlusions in acute ischemic stroke.
  • CREDO Stent Self-expandable microstent for the treatment of intracranial atherosclerotic disease (ICAD) and acute indications, including rescue stenting.
  • CREDO heal Stent HEAL Technology-coated version of the CREDO self-expandable microstent for intracranial stenosis and rescue stenting, with improved endothelialisation.
  • NeuroSpeed PTA Balloon Catheter Percutaneous transluminal angioplasty (PTA) balloon catheter for pre-dilation and treatment of intracranial arterial stenosis, used in combination with CREDO stents as part of Acandis' integrated ICAD Treatment System.
  • CARESTO heal Stent Third-generation carotid artery stent with HEAL antithrombogenic coating for the treatment of carotid artery disease, featuring high flexibility and full visibility.
  • NeuroBridge Catheter Intermediate catheter for neurovascular access and support during interventional procedures, used to facilitate delivery of therapeutic devices.
  • NeuroSlider Microcatheter Microcatheter for device delivery in neurovascular interventions, used as a delivery conduit for therapeutic devices such as stents and flow diverters.
  • NeuroSlider DLC (Micro)Catheter Dual-layer composite (DLC) microcatheter with enhanced trackability and support for delivery of flow diverters and other devices in neurovascular interventions. First Acandis product to receive CE certification under EU MDR (2023).
  • SiREX Stent Braided, fully radiopaque implant specifically designed for the treatment of disabling pulsatile tinnitus caused by lateral venous sinus stenosis. Currently under clinical investigation in the international RESOLVE study (78 patients across five European centres).
  • ICAD Treatment System Integrated treatment system combining the CREDO heal self-expanding microstent with the NeuroSpeed PTA balloon catheter for comprehensive intracranial atherosclerotic disease (ICAD) treatment in a single-pass endovascular therapy approach.

Quantifiable outcome

  • REVISAR study: Publication of clinical and angiographic outcomes for APERIO thrombectomy device in distal vessel occlusions (2025)
  • +2 more outcomes

Companies that use Acandis

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles1 record

Acandis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Acandis partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Hôpital Lariboisière PariscoreStrategic or Co-development PartnerCoordinating Principal Investigator site for the RESOLVE clinical study (SiREX Stent for pulsatile tinnitus). Prof. Emmanuel Houdart serves as Coordinating PI, with Dr. Alexis Guédon and Dr. Francesco Arpaia as clinical team members. The hospital is leading the international pivotal trial across five European centres with 78 patients.
  • Universitätsklinikum Hamburg-Eppendorf (UKE)coreStrategic or Co-development PartnerKey opinion leader site for multiple Acandis clinical studies. PD Dr. Maxim Bester is PI for the ACCERO (heal) PMCF registry (154 patients, NCT03957382) and the REheal study. UKE also hosts regular Acandis training workshops (DERIVO, ICA aneurysm training).
  • Städtisches Klinikum SolingencoreStrategic or Co-development PartnerKey clinical study site and training partner. PD Dr. Hannes Nordmeyer serves as coordinating PI for the CARESTAR study (536 patients, NCT07166731) and PI for the RECHRUT study (153 patients). The hospital hosts regular CREDO workshop training sessions.
  • Universitätsspital BaselcoreStrategic or Co-development PartnerLead site for the ICARUS investigator-initiated study (498 patients) evaluating CREDO heal Stent and NeuroSpeed PTA Balloon Catheter for ICAD-related stroke, directed by Prof. Dr. Marios Psychogios. Acandis is listed as a collaborator.
  • Universitätsklinikum BonncoreStrategic or Co-development PartnerPrincipal investigator site for the REVISAR PMCF study (130 patients, completed, results published 2025) evaluating APERIO thrombectomy devices. Prof. Dr. Franziska Dorn is the PI.
  • Universitätsklinikum MagdeburgcoreStrategic or Co-development PartnerPrincipal investigator site for the REheal PMCF study (352 patients, NCT05543447) evaluating the DERIVO 2heal Embolisation Device. Prof. Dr. Daniel Behme is the PI.
  • LINNC ParisminorGTM or Marketing PartnerAcandis participates in the annual LINNC Paris conference (1–3 June 2026), a major neurointervention educational event, as an exhibitor and presenter of clinical data.
  • ESMINT (European Society of Minimally Invasive Neurological Therapy)minorGTM or Marketing PartnerAcandis has participated as an exhibitor at ESMINT annual congresses (2024 Marseille, 2025 Marseille, 2026 Marseille) and hosts an annual Distributor Meeting alongside ESMINT.
  • SOBRICE (Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular)minorGTM or Marketing PartnerAcandis has participated at SOBRICE annual meetings (2021, 2022, 2024) in São Paulo, Brazil, supporting its Latin American distributor and subsidiary presence.

Scale indicators6 records

Recent moves13 records

Expansion highlights7 records

Acandis competitors and assessment

Company assessment

Broad incumbents

  • Stryker (Neurovascular): Stryker's Neurovascular division (formed via the acquisition of Cerenovus-related assets and others) is a global leader in hemorrhagic and ischemic stroke devices, including flow diverters (Surpass), stent retrievers (Trevo), and detachable coils. Directly competes with Acandis' DERIVO flow diverters and APERIO thrombectomy devices across hospitals globally.
  • Cerenovus (Johnson & Johnson MedTech): Cerenovus is J&J's neurovascular franchise offering a comprehensive portfolio of coils, flow diverters, stent retrievers, and access devices. Direct overlap with Acandis across both hemorrhagic (coils/flow diversion) and ischemic stroke (stent retrievers) categories.
  • Medtronic Neurovascular: Medtronic's Neurovascular business (inheriting Covidien/Stryker-era assets) competes across the full stroke spectrum including Pipeline flow diverters and Solitaire stent retrievers. As one of the largest medical device companies globally, Medtronic's scale, hospital contracts, and R&D resources make it Acandis' most formidable direct competitor.

Emerging players

  • InspireMD: InspireMD develops neurovascular and carotid stents with mesh protection technology (CGuard). Comparable to Acandis' CARESTO carotid stent franchise and DERIVO flow diverter technology, serving overlapping customer base.
  • MIVI Neuroscience: MIVI Neuroscience develops stroke treatment devices including the Q Aspiration catheter and Revive SE stent retriever. Direct competitor to Acandis' APERIO thrombectomy line, with overlapping target customers in stroke centers.

Direct peers

  • Wallaby Medical (Phenox): Wallaby Medical (acquired by Phenox) develops the Avenir coil system and other neurovascular devices. Direct peer to Acandis in the aneurysm treatment category with overlapping geographic coverage and target customers.
  • Penumbra: Penumbra is a U.S.-listed neurovascular company specializing in mechanical thrombectomy (aspiration-based, e.g., RED, Jet), stroke catheters, and more recently embolization devices. Direct competitor to Acandis' APERIO stent-retriever thrombectomy franchise and increasingly in flow diversion, with a strong U.S. commercial footprint.
  • Rapid Medical: Rapid Medical is an Israel-based neurovascular company developing adjustable stent retrievers (Tigertriever) and flow diverters (Comaneci). Direct peer with comparable focus on ischemic and hemorrhagic stroke, recently acquired by MicroPort further escalating competitive intensity.
  • Phenox GmbH: Phenox is a German neurovascular device company offering pCONUS stents, p64 flow diverters, and pRESET stent retrievers. A direct peer with similar product portfolio, German origin, and target customer base (interventional neuroradiologists) competing head-to-head with Acandis in Europe.
  • MicroPort NeuroTech: MicroPort NeuroTech (part of Shanghai MicroPort Medical) develops and markets the Tubridge flow diverter and other neurovascular devices. Directly comparable to Acandis in flow diversion technology with competing global commercial reach, particularly in China and Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Acandis social profiles

Digital presence

Acandis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acandis leadership team

Management profile

Number of profiles

Profiles2 records

Acandis subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Acandis funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acandis M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acandis

What does Acandis do?

Acandis develops, manufactures, and commercialises miniaturised implantable medical devices for the endovascular treatment of neurovascular diseases, including braided and laser-cut stents, flow diverters, mechanical thrombectomy devices, PTA balloon catheters, and microcatheters for stroke treatment. The company sells single-use implants to hospitals and interventional neuroradiology departments through a global network of direct subsidiaries and distributors across 60+ countries.

Is Acandis a public or private company?

Acandis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Acandis founded?

Acandis was founded in 2006. It employs 101 to 250 people.

Where is Acandis based?

Acandis is headquartered in Pforzheim, Germany, in the Europe region.

How does Acandis make money?

One revenue line is on record: medical Device Sales.

Who are Acandis's main competitors?

Broad incumbents on record are Stryker (Neurovascular), Cerenovus (Johnson & Johnson MedTech) and Medtronic Neurovascular. Emerging players are InspireMD and MIVI Neuroscience. Direct peers are Wallaby Medical (Phenox), Penumbra, Rapid Medical, Phenox GmbH and MicroPort NeuroTech.

Does Acandis have an API?

No public API is recorded for Acandis.

What industry is Acandis in?

Acandis's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizLauxera Closes €520M Fund as European Healthtech Investors Push for U.S. ScaleLauxera Capital Partners has closed its second fund, Lauxera Growth II, at €520 million, surpassing its €500 million hard cap and nearly doubling the size of its inaugural fund, with backing from returning and new institutional investors across Europe, Latin America, and the United States. The Paris- and San Francisco-based investment firm, which manages over $1 billion in assets across 13 portfolio companies, focuses on bridging European healthtech innovation with U.S. commercial scale, targeting investments of €20–50 million per company in commercial-stage healthcare technology businesses. Two investments have already been completed from the fund: a minority stake in German neurovascular device company Acandis and a majority stake in Swedish imaging contract research organization Antaros Medical.openPR.comMechanical Thrombectomy Devices Market Key Players Analysis - Boston Scientific Corporation, Straub Medical AG, AngioDynamics, Acandis GmbH, NIPRO.Insightace Analytics released a market assessment of the global mechanical thrombectomy devices market, valuing it at $1.42 billion in 2023. The market is projected to reach $2.43 billion by 2031, a CAGR of 7.06%. North America is expected to remain the leading region.PR NewswireMentice and Acandis GmbH announce a 3-year agreement for Mentice Ankyras clinical support software solutions at a value of 8.9mSEKMentice AB and Acandis GmbH have signed a 3-year collaboration agreement valued at 8.9 million SEK, under which Mentice will supply its Ankyras clinical support software solutions to Acandis for use with the latter's neurovascular medical devices. The partnership extends an existing relationship, with both companies citing successful clinical results and expressing optimism about further enhancing patient treatment outcomes in neurovascular interventions. The agreement was signed on October 25, 2022, and submitted for publication pursuant to EU Market Abuse Regulation.PR NewswireMentice and Acandis GmbH announce a 3-year agreement for Mentice Ankyras clinical support software solutions at a value of 8.9mSEKMentice AB, a Gothenburg-based leader in simulation solutions for image-guided interventional therapies, signed a 3-year collaboration agreement with Acandis GmbH, a Pforzheim-based innovator of minimally invasive devices for neurovascular disease treatment. The agreement, valued at 8.9 million SEK, covers Mentice's Ankyras clinical support software solutions to be integrated with Acandis's clinical support platform for treating neurovascular diseases. The partnership aims to enhance patient safety and treatment outcomes in cerebral aneurysm procedures, building on successful prior results achieved using Ankyras simulation with Acandis's devices.PR NewswireFlow Diversion Aneurysm Treatment Market records a CAGR of 8.26% by 2025|TechnavioTechnavio released a market research report projecting the flow diversion aneurysm treatment market will grow at a CAGR of 8.26% with incremental growth of USD 1.75 billion during 2021-2025. The report identifies Acandis GmbH, Boston Scientific Corp., and Cardinal Health Inc. as major participants, with market drivers including increasing prevalence of intracranial aneurysms, growing preference for flow diversion treatments, and improved detection of unruptured aneurysms. The COVID-19 impact on this medical devices market segment is also analyzed in the report.